Patents Examined by Keith C. Furman
  • Patent number: 5241050
    Abstract: From a cDNA library, a nucleotide sequence of a novel gene, called rig, specifically expressed by streptozotocin- or alloxan-nicotinamide-induced rat insulinomas was determined and an amino acid sequence of a protein encoded by the gene was deduced. Further, novel genes with base sequences homologous to rig were found in a BK virus-induced hamster insulinoma and in a surgically removed human insulinoma. The above DNA is transcribed to provide an mRNA. The above novel proteins, DNAs and mRNAs can be efficaciously employed for the medical purposes of pancreatic diseases.
    Type: Grant
    Filed: December 18, 1990
    Date of Patent: August 31, 1993
    Assignee: Tohoku University
    Inventor: Hiroshi Okamoto
  • Patent number: 5239056
    Abstract: A peptide fraction inducing the formation of antibodies which protect against the bovine leukemia virus (BLV), wherein it includes a peptide sequence which reproduces all or part of the sequence of the glycoprotein envelope gp51 fragment of the BLV virus which bears at least one of the epitopes (F, G, H) responsible for the biological activity of the virus. This fraction may be the fragment itself or a synthetic peptide. Application is made to the preparation or search for antibodies, to diagnosis and to the preparation of vaccines.
    Type: Grant
    Filed: February 5, 1992
    Date of Patent: August 24, 1993
    Assignee: Rhone Merieux
    Inventors: Daniel G. J. G. Portetellie, Arsene Leon G. Burny, Corine F. Dandoy, Helene S. C. Gras, nee Masse, Andre L. Tartar
  • Patent number: 5225537
    Abstract: Methods are disclosed for producing hybrid phospholipid-binding proteins from eukaryotic cells. DNA constructs comprising a transcriptional promoter, at least one signal sequence and a hybrid phospholipid-binding protein coding sequence comprising at least one lipocortin lipid-binding domain joined to a gla-domainless, vitamin K-dependent protein and a transcriptional terminator are also disclosed.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: July 6, 1993
    Assignee: ZymoGenetics, Inc.
    Inventor: Donald C. Foster
  • Patent number: 5206347
    Abstract: A method of isolating cell surface receptors utilizing a short peptide sequence bound to an affinity column. Cell surface receptors which bind selectively to the short peptide and which are specific to various adhesion proteins may be isolated therewith from various cell preparations. These receptors, whose functional integrity has been maintained by the presence of the peptide ligand, are incorporated into liposomes and used to deliver specific compounds inside the liposomes to select tissues containing the specific adhesion proteins.
    Type: Grant
    Filed: July 13, 1990
    Date of Patent: April 27, 1993
    Assignee: La Jolla Cancer Research Foundation
    Inventors: Erkki I. Ruoslahti, Michael D. Pierschbacher
  • Patent number: 5202426
    Abstract: Eucaryotic NAD cyclases able to cause production of cyclic adenosine diphosphate ribose from nicotinamide adenine dinucleotide.
    Type: Grant
    Filed: December 17, 1990
    Date of Patent: April 13, 1993
    Assignee: Marine Biological Laboratory
    Inventors: Felix Strumwasser, Mark R. Hellmich, David L. Glick
  • Patent number: 5200510
    Abstract: Methods for purifying factor VIII:C, von Willebrand factor (vWF) or complexes thereof from heterogeneous biological fluids are disclosed. The methods utilize a binding peptide, specific to either factor VIII:C or vWF, bound to an insoluble matrix. Peptides suitable for use within the methods are also disclosed.
    Type: Grant
    Filed: March 2, 1988
    Date of Patent: April 6, 1993
    Assignee: ZymoGenetics, Inc.
    Inventors: Anur A. Kumar, Frederick S. Hagen, Andrzej Z. Sledziewski
  • Patent number: 5200509
    Abstract: This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps.This invention also relates to DNA molecules encoding human somatomedin carrier protein-like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein-like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: April 6, 1993
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Emerald M. Spencer, Carol Talkington-Verser
  • Patent number: 5198423
    Abstract: This invention relates to a functional polypeptide containing the binding domain of human fibronectin and the heparin-binding domain of human fibronectin.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: March 30, 1993
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Yuki Taguchi, Yoh'ichi Ohdate, Yasutoshi Kawase, Shouichi Goto, Fusao Kimizuka, Ikunoshin Kato, Ikuo Saiki, Ichiro Azuma
  • Patent number: 5196516
    Abstract: The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention.
    Type: Grant
    Filed: July 21, 1989
    Date of Patent: March 23, 1993
    Assignee: Akzo N.V.
    Inventors: Christa S. Schreurs, Thomas C. Mettenleiter, Artur J. Simon, Noemi Lukacs, Hanns J. Rziha
  • Patent number: 5187260
    Abstract: A process is disclosed in which high purity protamine-DNA complexes are prepared by collecting nucleoprotamines specific developmental stages of a life form, specifically, amphibian, egg by low temperature processing. The process also includes the steps of sequential homogenization in a high concentration aqueous salt solution at a buffered low pH, followed by ultracentrifugation to remove insoluble matter. Either a crude mixture or pure isolate of the complexes may be produced. Pure isolates require aqueous chloroform extraction to isolate protein and to remove lipids. Lyophilization then removes chloroform and excess water. The isolate is then fractionated by single pass alumina chromatography. Dialysis against pure water removes salts. Repeated lyophilization removes excess water and concentrates single protamines and protamine-like proteins. The mixture may then be reconstituted with 5% weight/volume heterologous or homologous DNA, in order to shield from charge toxicity.
    Type: Grant
    Filed: April 15, 1991
    Date of Patent: February 16, 1993
    Inventors: Sharifa Karali, John K. Barberii
  • Patent number: 5187262
    Abstract: A cDNA clone (HEV1) encoding hevein was isolated via polymerase chain reaction (PCR) using mixed oligonucleotides corresponding to two regions of hevein as primers and a Hevea brasiliensis latex cDNA library as a template. HEV1 is 1018 nucleotides long and includes an open reading frame of 204 amino acids. The deduced amino acid sequence contains a puGOVERNMENT RIGHTSThis application was funded under Department of Energy Contract DE-AC02-76ER01338. The U.S. Government has certain rights under this application and any patent issuing thereon.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: February 16, 1993
    Assignee: Board of Trustees, operating Michigan State University
    Inventors: Natasha V. Raikhel, Willem F. Broekaert, Nam-Hai Chua, Anil Kush
  • Patent number: 5187261
    Abstract: Mature human serum albumin is produced from a human serum albumin produced by a microbiological route in the form of fused protein ("pseudo-pro-HSA") containing an N-terminal peptide elongation.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: February 16, 1993
    Assignee: Genetica
    Inventors: Martine Latta, Jean-Francois Mayaux, Paolo Sarmientos
  • Patent number: 5185323
    Abstract: Antimaturation factor (platelet factor 4 or active peptide segments thereof) is employed in the clinical treatment of coagulation disorders as an anticoagulant operating via an autoregulator mechanism for selectively suppressing megakaryocytopoiesis. Exposure of immature megakaryocytes to antimaturation factor reversibly inhibits cell maturation and, accordingly, functions characteristic of the mature cell, including platelet production and expression of genes coding for platelet coagulation factors, are reversibly suppressed.
    Type: Grant
    Filed: March 31, 1988
    Date of Patent: February 9, 1993
    Assignee: Temple University
    Inventor: Alan M. Gewirtz
  • Patent number: 5179196
    Abstract: The present invention provides a process for the recovery of heterologous proteins from CTAP-III fusion proteins comprising expressing a fusion protein having a first amino acid sequence, a second amino acid sequence, and a selectable site which may be cleaved to provide first and second polypeptide fragments, respectively, wherein the first amino acid fragment is homologous to CTAP-III, and the first and second fragments have different pI values; cleaving the fusion protein to provide the first and second fragments; and separating the first and second fragments by ion exchange chromatography.
    Type: Grant
    Filed: May 4, 1989
    Date of Patent: January 12, 1993
    Assignee: SRI International
    Inventors: Paul H. Johnson, Ping Sze, Richard C. Winant, Jerome B. Lazar
  • Patent number: 5179198
    Abstract: The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.
    Type: Grant
    Filed: July 7, 1989
    Date of Patent: January 12, 1993
    Assignees: Hidechika Okada, Mitsubishi Corporation
    Inventors: Hidechika Okada, Noriko Okada, Yoichi Nagami, Kazuhiro Takahashi, Hisao Takizawa, Jun Kondo
  • Patent number: 5177190
    Abstract: A method is disclosed for isolating and purifying C5a receptor from human polymorphonuclear leukocytes. C5a is a complement-derived protein which is important as a mediator of inflammatory responses. C5a receptor may be used to screen create and quantify C5a antagonists useful as anti-inflammatory agents and immunoregulants and to generate monoclonal and polyclonal anti-C5a receptor antibodies useful as anti-inflammatory agents and immunoregulants.
    Type: Grant
    Filed: January 22, 1992
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Thomas E. Rollins, Martin S. Springer
  • Patent number: 5171842
    Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps.
    Type: Grant
    Filed: November 1, 1991
    Date of Patent: December 15, 1992
    Assignee: American Cyanamid Company
    Inventors: Peter Bohlen, Peter Gautschi-Sova
  • Patent number: 5169936
    Abstract: A process for the purification of proteins from solutions containing contaminants of similar net charge and molecular weight is provided, comprising contacting a solution containing the desired protein with an immobilized metal affinity chromatography resin in a buffer containing a low concentration of a weak ligand for the chelant of the resin. The adsorbed protein is then eluted using a buffer having a high concentration of the same weak ligand, e.g., Tris. Particularly preferred features employ agarose-iminodiacetic acid resins having copper cations and are especially useful in obtaining preparations of homogeneous, stable rsT4 proteins.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: December 8, 1992
    Assignee: Biogen, Inc.
    Inventors: Mark A. Staples, Christopher A. Pargellis
  • Patent number: 5164489
    Abstract: The invention relates to the purification and characterization of growth stimulatory and inhibitory protein factors produced by various organs which appear to play a role in the successful formation of metastatic colonies of tumor cells. In particular, it has been found that syngeneic organs secrete protein growth stimulatory and inhibitory factors which can, at low concentrations, affect metastatic tumor cells. The ability of a malignant cell to respond to these factors is believed to be related to tumor cell metastasis to specific body organs. In particular a lung growth stimulatory glycoprotein having a molecular weight of approximately 66,000 daltons has been found to stimulate growth of lung-metastatic rat and human mammary tumor cells in serum deprived medium.
    Type: Grant
    Filed: May 23, 1988
    Date of Patent: November 17, 1992
    Assignee: Board of Regents, University of Texas System
    Inventors: Garth L. Nicolson, Philip G. Cavanaugh
  • Patent number: 5149529
    Abstract: A method for preventing or ameliorating HSV infection in a bird or mammal comprises administering a composition comprising an effective amount of an HSV surface glycoprotein and an effective amount of an MDP equivalent, encapsulated in liposomes. The resulting composition is useful for reducing the severity and recurrence of HSV outbreaks.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: September 22, 1992
    Assignees: Board of Trustees of Leland Chiron Corporation, Stanford Junior University
    Inventors: Rodney Ho, Thomas Merigan, Rae L. Burke, Dino Dina